BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27127301)

  • 21. Second-generation inhibitors of Bruton tyrosine kinase.
    Wu J; Liu C; Tsui ST; Liu D
    J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.
    Cohen JB; Han X; Jemal A; Ward EM; Flowers CR
    Cancer; 2016 Aug; 122(15):2356-63. PubMed ID: 27153197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of B-cell receptor signalling in B-cell malignancies.
    Jerkeman M; Hallek M; Dreyling M; Thieblemont C; Kimby E; Staudt L
    J Intern Med; 2017 Nov; 282(5):415-428. PubMed ID: 28295729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage.
    Queirós AC; Beekman R; Vilarrasa-Blasi R; Duran-Ferrer M; Clot G; Merkel A; Raineri E; Russiñol N; Castellano G; Beà S; Navarro A; Kulis M; Verdaguer-Dot N; Jares P; Enjuanes A; Calasanz MJ; Bergmann A; Vater I; Salaverría I; van de Werken HJG; Wilson WH; Datta A; Flicek P; Royo R; Martens J; Giné E; Lopez-Guillermo A; Stunnenberg HG; Klapper W; Pott C; Heath S; Gut IG; Siebert R; Campo E; Martín-Subero JI
    Cancer Cell; 2016 Nov; 30(5):806-821. PubMed ID: 27846393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
    Brown JR; Harb WA; Hill BT; Gabrilove J; Sharman JP; Schreeder MT; Barr PM; Foran JM; Miller TP; Burger JA; Kelly KR; Mahadevan D; Ma S; Li Y; Pierce DW; Barnett E; Marine J; Miranda M; Azaryan A; Yu X; Nava-Parada P; Mei J; Kipps TJ
    Haematologica; 2016 Jul; 101(7):e295-8. PubMed ID: 27151992
    [No Abstract]   [Full Text] [Related]  

  • 26. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
    Atilla E; Atilla PA; Demirer T
    Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sun B, Shah B, Fiskus W, et al. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015;126(13):1565-1574.
    Blood; 2016 Sep; 128(13):1778. PubMed ID: 27688783
    [No Abstract]   [Full Text] [Related]  

  • 29. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
    Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Grønbæk K; Sundberg J; Pedersen LB; Ralfkiær E; Karjalainen-Lindsberg ML; Sundström C; Ehinger M; Geisler C; Jerkeman M
    Blood; 2016 Oct; 128(14):1814-1820. PubMed ID: 27354719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The genetics of nodal marginal zone lymphoma.
    Spina V; Khiabanian H; Messina M; Monti S; Cascione L; Bruscaggin A; Spaccarotella E; Holmes AB; Arcaini L; Lucioni M; Tabbò F; Zairis S; Diop F; Cerri M; Chiaretti S; Marasca R; Ponzoni M; Deaglio S; Ramponi A; Tiacci E; Pasqualucci L; Paulli M; Falini B; Inghirami G; Bertoni F; Foà R; Rabadan R; Gaidano G; Rossi D
    Blood; 2016 Sep; 128(10):1362-73. PubMed ID: 27335277
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
    Norman P
    Expert Opin Investig Drugs; 2016 Aug; 25(8):891-9. PubMed ID: 27148767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
    Tai YT; Acharya C; An G; Moschetta M; Zhong MY; Feng X; Cea M; Cagnetta A; Wen K; van Eenennaam H; van Elsas A; Qiu L; Richardson P; Munshi N; Anderson KC
    Blood; 2016 Jun; 127(25):3225-36. PubMed ID: 27127303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
    Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
    Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.
    Amin NA; Balasubramanian S; Saiya-Cork K; Shedden K; Hu N; Malek SN
    Clin Cancer Res; 2017 Feb; 23(4):1049-1059. PubMed ID: 27535981
    [No Abstract]   [Full Text] [Related]  

  • 35. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.
    Juskevicius D; Lorber T; Gsponer J; Perrina V; Ruiz C; Stenner-Liewen F; Dirnhofer S; Tzankov A
    Leukemia; 2016 Dec; 30(12):2385-2395. PubMed ID: 27198204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guidelines for the management of diffuse large B-cell lymphoma.
    Chaganti S; Illidge T; Barrington S; Mckay P; Linton K; Cwynarski K; McMillan A; Davies A; Stern S; Peggs K;
    Br J Haematol; 2016 Jul; 174(1):43-56. PubMed ID: 27196701
    [No Abstract]   [Full Text] [Related]  

  • 37. Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study.
    Ji D; Li Q; Cao J; Guo Y; Lv F; Liu X; Wang B; Wang L; Luo Z; Chang J; Wu X; Hong X
    Oncotarget; 2016 May; 7(22):33331-9. PubMed ID: 27129176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The molecular pathogenesis of mantle cell lymphoma.
    Vogt N; Dai B; Erdmann T; Berdel WE; Lenz G
    Leuk Lymphoma; 2017 Jul; 58(7):1530-1537. PubMed ID: 27894215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
    Landau DA; Sun C; Rosebrock D; Herman SEM; Fein J; Sivina M; Underbayev C; Liu D; Hoellenriegel J; Ravichandran S; Farooqui MZH; Zhang W; Cibulskis C; Zviran A; Neuberg DS; Livitz D; Bozic I; Leshchiner I; Getz G; Burger JA; Wiestner A; Wu CJ
    Nat Commun; 2017 Dec; 8(1):2185. PubMed ID: 29259203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
    Saba NS; Wong DH; Tanios G; Iyer JR; Lobelle-Rich P; Dadashian EL; Liu D; Fontan L; Flemington EK; Nichols CM; Underbayev C; Safah H; Melnick A; Wiestner A; Herman SEM
    Cancer Res; 2017 Dec; 77(24):7038-7048. PubMed ID: 28993409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.